Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SOX17
REST API REST API
Homo sapiens
SOX17 is differentially expressed in 156 experiments: 120 organism parts: lung, uterus, ... (118 more);, 138 disease states: normal, healthy, ... (136 more);, 40 cell types 129 cell lines 16 compound treatments and 66 other conditions.
Orthologs SOX17 (Bos taurus)   Sox17 (Mus musculus)   sox17 (Danio rerio)   Q4H2R8_CIOIN (Ciona intestinalis)   Sox17 (Rattus norvegicus)   Sox15 (Drosophila melanogaster)   sox17a (Xenopus laevis)   sox17b.2 (Xenopus laevis)   sox17b.1 (Xenopus laevis)   SOX17 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, negative regulation of cell growth, DNA binding, protein stabilization, protein binding, regulation of transcription, DNA-dependent, beta-catenin binding, embryonic heart tube development, stem cell differentiation, transcription, DNA-dependent, positive regulation of gene expression, endoderm formation, embryonic foregut morphogenesis, spermatogenesis, negative regulation of Wnt receptor signaling pathway, transcription factor binding, sequence-specific DNA binding, endoderm development, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, canonical Wnt receptor signaling pathway, regulation of cell differentiation, regulation of embryonic development, transcription factor complex, endodermal cell fate determination, negative regulation of transcription from RNA polymerase II promoter, gastrulation, positive regulation of transcription, DNA-dependent, embryonic organ development, outflow tract morphogenesis, embryonic heart tube morphogenesis, positive regulation of skeletal muscle tissue development, positive regulation of protein catabolic process, cell migration involved in gastrulation, endocardium formation, endodermal digestive tract morphogenesis, cardiac cell fate determination, protein destabilization, gall bladder development, vasculogenesis, heart formation, positive regulation of cell differentiation, negative regulation of mesodermal cell fate specification, stem cell fate specification, regulation of stem cell division, endocardial cell differentiation, renal system development, negative regulation of canonical Wnt receptor signaling pathway, heart looping, rostrocaudal neural tube patterning, regulation of mesodermal cell fate specification, sequence-specific DNA binding transcription factor activity, negative regulation of Wnt receptor signaling pathway involved in heart development, signal transduction involved in regulation of gene expression, transcription regulatory region DNA binding, common bile duct development, regulation of stem cell proliferation, cardiogenic plate morphogenesis, regulation of transcription from RNA polymerase II promoter involved in definitive endodermal cell fate specification, regulation of cardiac cell fate specification, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity, inner cell mass cellular morphogenesis
InterPro Term HMG_HMG1/HMG2, DUF3547
UniProt Accession Q9H6I2, Q2T9L5, Q2NKK5
Gene-Disease Assocation VESICOURETERAL REFLUX 3; VUR3
Search EB-eye ENSG00000164736
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, ... (21 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
K562
1
E-MTAB-37
SJRH30
1
E-MTAB-37
primary pancreatic ductal adenocarcinoma
1
E-MEXP-2826
C4II
1
E-MTAB-37
J82
1
E-MTAB-37
123 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, E-GEOD-21909, ... (25 experiments)

Factor Value U/D Experiments
1
2
E-TABM-130, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
endothelial cell
1
2
E-GEOD-3920, E-GEOD-19240, E-GEOD-3998
basophil
1
E-GEOD-3982
spheroid recovery
1
E-GEOD-4219
primary blood vessel endothelial cell
1
E-MEXP-66
34 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-MEXP-1121, E-TABM-15, ... (38 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
neuroblastoma
2
E-MTAB-62, E-MTAB-37
breast cancer
2
E-GEOD-22544, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
prostate cancer
1
E-GEOD-6919
myeloma
1
E-MTAB-317
132 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-1417, E-GEOD-3356, E-GEOD-995, ... (10 experiments)

Factor Value U/D Experiments
camptothecin
1
E-GEOD-1417
hydrogen peroxide
1
E-GEOD-5339
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
propofol
1
E-GEOD-4386
bacterial endotoxin
1
1
E-GEOD-3284
baseline sevoflurane
1
E-GEOD-4386
10 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
81
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-TABM-321, E-GEOD-17347, E-GEOD-21243 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20504, E-GEOD-22278, E-MEXP-1741

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-666, E-GEOD-19519, E-GEOD-6919, ... (15 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-3697, E-MEXP-1315, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Processing time: 0.328 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM